Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 May 5;15(6):750-751.
doi: 10.1021/acsmedchemlett.4c00178. eCollection 2024 Jun 13.

Novel Compounds as S1P5 Modulators for Treating Neurodegenerative Diseases

Ram W Sabnis  1 , Anika R Sabnis  2
Affiliations
Editorial

Novel Compounds as S1P5 Modulators for Treating Neurodegenerative Diseases

Ram W Sabnis et al. ACS Med Chem Lett. .

Abstract

Provided herein are novel compounds as S1P5 modulators, pharmaceutical compositions, use of such compounds in treating neurodegenerative diseases, particularly Alzheimer's disease, multiple sclerosis, migraine and amyotrophic lateral sclerosis, and processes for preparing such compounds.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Similar articles

See all similar articles

References

    1. Lebmann V.; Kartalou G.; Endres T.; Pawlitzki M.; Gottmann K. Repurposing drugs against Alzheimer’s disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD?. J. Neural Transm. 2023, 130, 1003–1012. 10.1007/s00702-023-02618-5. - DOI - PMC - PubMed
    1. Kandjani O. J.; Yaqoubi S.; Vahdati S. S.; Borhannejad B.; Dastmalchi S.; Alizadeh A. A. S1PR1 modulators in multiple sclerosis: Efficacy, safety, comparison, and chemical structure insights. Eur. J. Med. Chem. 2023, 250, 115182. 10.1016/j.ejmech.2023.115182. - DOI - PubMed
    1. Colombo E.; Farina C. Lessons from S1P receptor targeting in multiple sclerosis. Pharmacol. Ther. 2022, 230, 107971. 10.1016/j.pharmthera.2021.107971. - DOI - PubMed
    1. Cohan S. L.; Benedict R. H. B.; Cree B. A. C.; DeLuca J.; Hua L. H.; Chun J. The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis. CNS Drugs 2022, 36, 703–719. 10.1007/s40263-022-00927-z. - DOI - PMC - PubMed
    1. Sabnis R. W.; Sabnis A. R. Carboxylic Acid-Containing Indanyl Compounds as S1P5 Modulators for Treating Neurodegenerative Diseases. ACS Med. Chem. Lett. 2023, 14, 1033–1034. 10.1021/acsmedchemlett.3c00272. - DOI - PMC - PubMed

Publication types

LinkOut - more resources